Abbott Breakup Plans Are on Target as Profit Tops Estimates

Abbott Laboratories, splitting into a drugmaker and a diversified health-care business, reported earnings that beat analysts’ estimates and raised its 2012 forecast as sales jumped more than expected for its top product.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.